Contemporary Tendencies in Surgical Treatment and Biopsy of Sentinel Lymph Nodes in Malignant Melanoma of the Skin

Strahil Strashilov¹, Veselin Kirov², Angel Yordanov³* and Vasil Nanev⁴

¹Department of Plastic Restorative, Reconstructive and Aesthetic Surgery, Europe
²Department of Oncodermatology, University Hospital "Dr. Georgi Stranski"-Pleven, Europe
³Clinic of Gynecologic Oncology, University Hospital "Dr. Georgi Stranski"-Pleven, Europe
⁴Department of Surgical Oncology, Medical University Pleven, Europe

Submission: September 24, 2017; Published: October 05, 2017

*Corresponding author: Angel Yordanov, Clinic of Gynecologic Oncology, University Hospital "Dr. Georgi Stranski"-Pleven, Bulgaria, Europe, Tel: 359887 671520; Email: angel.yordanov@gmail.com

Abstract

The malignant melanoma is a fairly rare, but very malignant tumor, emanative from epidermal melanocytes, that affects the skin in above 95% of cases. Unlike other tumors, it is encountered in younger age and can metastasize in early stages of the disease. This tumor is with highest rate of morbidity increase - 5% of newly diagnosed oncological conditions in men and 6% in women. The surgical treatment includes biopsy of the primary lesion, sentinel biopsy of regional lymph nodes with possible following lymph dissection, wide radical excision of the primary site and surgical removal of distant metastases in the advanced stages of the disease.

Keywords: Malignant melanoma of the skin; Contemporary surgical treatment; Sentinel lymph biopsy

Introduction

The malignant melanoma (MM) is a fairly rare, but very malignant tumor, originating from the epidermal melanocytes. Its highest incidence is in the caucasian population of Australia and New Zealand, where the morbidity is above 40/100 000 people per year. In the USA its 10/100000, in Western Europe’s women it’s 12/100 000, while for men it’s 7/100000. For Bulgaria the morbidity is 3.0-3.5/100 000. Unlike other tumors, it affects younger age and can metastasize in early stages of the disease. MM is the tumor with highest rate of morbidity increase - 5% of newly diagnosed oncological conditions in men and 6% in women [1,2].

Contemporary surgical treatment of MM of the skin, including sentinel biopsy of regional lymph nodes, is very important and is a main part of the complex treatment, generally defining the outcome of the disease. The main components of the complex treatment are:

a) biopsy of the primary lesion (incisional or excisional)
b) pathological examination of the biopsy material with description of the thickness of the tumor based on Breslow and the invasion depth, based on Clark
c) radical reexcision of the tumor bed
d) performing sentinel biopsy of the regional lymph nodes if indicated
e) lymph dissection of regional lymph nodes if indicated
f) histopathological serial immunohistochemical analysis of sentinel lymph nodes and/or usual one for the rest of the lymph nodes [3-5]
g) staging the disease with the TNM classification
h) undertaking adjuvant non-surgical treatment, if needed
i) observation
j) Exposition
A. Biopsy of the primary lesion: it can be incisional, where a piece of bigger tumors is taken, or excisional, where the melanoma is removed with visibly healthy halo of unchanged skin with size between 1 and 3 mm. The reason to not go straight for radical excision of the tumor site is that it would cut off lymph pathways, which directly drain the location, and that would vitiate the biopsy of the sentinel lymph node, which is with a specific area of lymph drainage.

B. Pathological examination of the biopsy material: it gives a description of the tumor thickness according to Breslow scale (Table 1) and of the depth of invasion according to Clark (Table 2) [6].

Table 1: The tumor thickness according Breslow scale.

<table>
<thead>
<tr>
<th>Lesion thickness by Breslow (mm)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>In situ</td>
<td>non-invasive melanoma</td>
</tr>
<tr>
<td>≤1</td>
<td>thin melanoma</td>
</tr>
<tr>
<td>1–4</td>
<td>intermediate melanoma</td>
</tr>
<tr>
<td>&gt;4</td>
<td>thick melanoma</td>
</tr>
</tbody>
</table>

Table 2: The depth of invasion according to Clark.

<table>
<thead>
<tr>
<th>Depth of invasion by Clark</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clark I</td>
<td>Melanoma confined to the epidermis (melanoma in situ)</td>
</tr>
<tr>
<td>Clark II</td>
<td>Invasion into the papillary dermis</td>
</tr>
<tr>
<td>Clark III</td>
<td>Invasion to the junction of the papillary and reticular dermis</td>
</tr>
<tr>
<td>Clark IV</td>
<td>Invasion into the reticular dermis</td>
</tr>
<tr>
<td>Clark V</td>
<td>Invasion into the subcutaneous fat</td>
</tr>
</tbody>
</table>

C. Radical reexcision of the tumor bed: it is performed 4-6 weeks after diagnosing [7]. Part of the skin in the area around the primary tumor is surgically removed after performing a sentinel biopsy (if such is done). The distance of the reexcisional line on both sides from the cicatrix from the previous biopsy of the melanoma or from itself is correlative to the tumor’s depth, established with the pathological examination (Table 3) [8-13].

Table 3: Relationship between the surgical borders and the tumor’s depth.

<table>
<thead>
<tr>
<th>Lesion depth by Breslow (mm)</th>
<th>Surgical borders</th>
</tr>
</thead>
<tbody>
<tr>
<td>In situ</td>
<td>0.5-1.0 cm.</td>
</tr>
<tr>
<td>≤1</td>
<td>1.0 cm.</td>
</tr>
<tr>
<td>1–2</td>
<td>1.0 – 2.0 cm.</td>
</tr>
<tr>
<td>&gt;2</td>
<td>2.0 cm.</td>
</tr>
</tbody>
</table>

D. Performing sentinel biopsy of the regional lymph nodes: According to the data from the most recent and wide studies (MSLT 1 and 2) sentinel biopsy of lymph nodes is a foundation in the complex treatment of the disease. They prove mainly four things: first - the result of the biopsy is one of the strongest prognostic factors, second - the execution of total lymphadenectomy after positive sentinel biopsy in patients with some thin, all intermediate and thick melanomas, significantly increases the survival rate in good health, third - the result of the biopsy is base for an effective adjuvant therapy and fourth - sentinel biopsy is very gentle surgical intervention [14,15]. Sentinel biopsy is the removal of the first lymph node(s) that receive the metastases of a malignant process. Histological examination of that node gives accurate prognosis about the affecting of the remaining lymph node chain [16,17]. Introducing biopsy of the sentinel lymph nodes in cases of malignant melanoma of the skin is done by Donald Morton et al. in 1992 to avoid common postoperative complications of the previously routinely used elective lymph dissection and the lack of effect by it on negative lymph nodes [18,19].

i. Indications for performing sentinel biopsy:
   a. clinically negative regional lymph nodes
   b. tumor thickness over 1 mm
   c. for tumors between 0.76 and 1 mm, performing the intervention must be discussed and it must be precise
   d. for tumors with thickness under 0.75 mm sentinel lymph node biopsy is performed only by exception and in the presence of additional factors, such as tumor ulcerations, higher mitotic index, young age, etc [20-23].

ii. Contraindications against performing sentinel biopsy:
   a. most tumors with thickness under 0.75mm
   b. clinically and puncture-biopsy positive regional lymph nodes
   c. previous lymph biopsy of that region
   d. performed wide-bordered primary site biopsy
   e. lack of a team of prepared specialists [24].

I. Technique for performing sentinel lymph node biopsy

Nowadays we use the following methodology: biopsy of sentinel lymph nodes in case of MM is performed after the initial injection of radiopharmaceutical 99Tc sulfur colloid at 4 intradermal spots around the scar of a previous biopsy of the melanoma of the skin is done by Donald Morton et al. in 1992 to avoid common postoperative complications of the previously routinely used elective lymph dissection and the lack of effect by it on negative lymph nodes [18,19].
A sentinel lymph node is considered one that is colored in blue and topographically fits on the lymphoscintigraphic map. That node is removed after disturbing the afferent and efferent lymph vessels and then sent for histological search of metastases [29,30]. By this method we reached 98% success in finding the sentinel lymph node. There is another widely used method for sentinel biopsy - after doing the lymphoscintigraphic map, a search for the lymph node is performed with manual intraoperative gamma camera. There is also an option to use just the latter pre- and intraoperative, without making a lymphoscintigraphic map [31]. The success rate of those methods is similar to ours, but our method is significantly cheaper and economically efficient, and therefore a method of choice.

E. Lymph dissection of regional lymph nodes: it is the standart surgical removal of the corresponding lymph nodes, if those are affected by metastatic process, which is found histologically or citologically after a sentinel biopsy. clinical or apparatus suspicion [32]. According to the data from the most recent and wide studies on sentinel biopsy and lymph dissection in case of MM of the skin (MSLT 1 and 2), performing the dissection immediately after finding a positive sentinel lymph node increases the survivability of patients in good health, compared to those, where lymph dissection is performed after the clinical finding of metastases in the lymph nodes [14,15].

F. Histopathological examination of the removed sentinel and other lymph nodes: after removing the sentinel lymph nodes they are tested with serial section immunohistochemistry with markers, specific for the melanoma cells (S100, Melan A, HMB-45) for the presence of metastases, micrometastases or isolated tumor cells [33-36]. The correlation between skin melanoma thickness and percentage of positive sentinel lymph nodes is shown in table 4 [37]. Lymph nodes, removed by dissection, are also subjected to standart or immunohistochemical histopathological examination for metastases.

<table>
<thead>
<tr>
<th>Lesion thickness by Breslow (mm)</th>
<th>Positive sentinel lymph nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 1</td>
<td>5%</td>
</tr>
<tr>
<td>1-4</td>
<td>15-20%</td>
</tr>
<tr>
<td>&gt;4</td>
<td>&gt;40%</td>
</tr>
</tbody>
</table>

G. Disease staging: it is performed after all said procedures, with the TNM system, in 4 clinical stages. It is a very important step in the treatment of malignant melanoma of the skin, because the success of the following treatment depends on it.

H. Adjuvant treatment: all other therapies are included here, besides the surgical (immunotherapy, target therapy, vaccinotherapy, chemotherapy, radiotherapy, etc)
patients treated with excision only compared with excision biopsy followed by wider local excision. Br J Dermatol 150: 523-530.

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editoral service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
  - (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php

How to cite this article: Strahl S, Veselin K, Angel Y, Vasil N. Contemporary Tendencies in Surgical Treatment and Biopsy of Sentinel Lymph Nodes in Malignant Melanoma of the Skin. Open Access J Surg. 2017; 6(2): 555685. DOI: 10.19080/OAJS.2017.06.555685.